Recent tumor genome sequencing studies have established the prevalence of mutant Kras in Pancreatic Intraepithelial Neoplasia (PanINs), the most common precursor lesions (Kanda et al., 2012), and in pancreatic cancer (Jones et al., 2008; Biankin et al., 2012) with increased precision. This evidence concerns the gene KRAS and familial pancreatic carcinoma.